#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
proLékaře.cz

Internal Medicine - Issue 6/2013

80th birthday prof. MUDr. Karla Horkého, DrSc., FACP (Hon.)

433
The origins of the Czech Society of Cardiology and of Czech cardiology

J. Widimský

440
Up‑ to‑ day trends in insulin therapy

A. Adamíková, J. Rybka

444
Impact of aortic stiffness on central hemodynamics and cardiovascular system

J. Bulas, M. Potočárová, M. Filková, A. Šimková, J. Murín

450
Lipids and the size of lipoprotein particles in newly dia­gnosed and untreated patients with type 2 diabetes mellitus

A. Dukát, Ľ. Fábryová, S. Oravec, P. Sabaka, L. Mistríková, D. Baláž, P. Gavornik, Ľ. Gašpar

453
Metabolic syndrome and prediabetic states

P. Galajda, Michal Mokáň, Marián Mokáň

459
Resistant hypertension in the elderly

Ľ. Gašpar, I. Balažovjech

463
Epigenetic cancer drugs and their role in anticancer therapy

P. Klener

466
The environmental estrogen bisphenol A and its effects on the human organism

Z. Lazúrová, I. Lazúrová

472
Impact of pregnancy on pituitary disorders

J. Marek

478
Differential dia­gnosis and treatment of hyponatremia

M. Mydlík, K. Derzsiová, K. Frank

482
Adherence and persistence with a focus on the treatment of hypertensive patients

M. Souček

486
Diuretics in monotherapy and in combination with other diuretics and non‑diuretics in the treatment of hypertension

J. Špinar, L. Špinarová, J. Vítovec

496
Hypertension in patients with polycystic kidney disease –  incidence, pathogenesis, prognosis, therapy

V. Tesař, J. Reiterová

501
Primary hyperaldosteronism: common cause of secondary hypertension with higher cardiovascular risk

J. Widimský jr.

Guidelines

505
Chronic obstructive pulmonary disease in the light of new guidelines –  brief summary of phenotypically oriented guidelines for non‑pulmonary physicans

V. Koblížek, J. Chlumský, V. Zindr, K. Neumannová, J. Zatloukal, V. Sedlák, J. Kociánová, J. Zatloukal, B. Novotná

Original Contributions

516
The effectiveness of anagrelide treatment in patients with Ph‑ negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012

M. Penka, J. Schwarz, P. Ovesná, L. Červinek, P. Ďulíček, D. Pospíšilová, J. Kissová, T. Pavlík, Kolektiv České Pracovní Skupiny Pro Myeloproliferativní Choroby (czemp)

Internal Medicine

Issue 6
2013 Issue 6
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#